You are here

Genmab

Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results

Roche Up, J&J Down as Cancer Drug Combos Yield More Mixed Results

Xconomy

clinical trials

Flag link:

Danish biotech Genmab hit by ending of trial using key cancer drug

Danish biotech Genmab hit by ending of trial using key cancer drug

Reuters

Flag link:

Genmab hits roadblock in non-Hodgkin lymphoma

Genmab hits roadblock in non-Hodgkin lymphoma

Biopharma Dive

non-Hodgkin's lymphoma

clinical trials

Flag link:

Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.

Novartis, feeling the heat from head-to-head rivals, pulls Arzerra outside the U.S.

Fierce Pharma

chronic lymphocytic leukemia

Flag link:

Genmab and J&J 'love' partnership as some ponder takeover

Genmab and J&J 'love' partnership as some ponder takeover

Yahoo/Reuters

Flag link:

Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort

Seven years in the making, Seattle Genetics picks up early option on Genmab’s ADC effort

Endpoints

Seattle Genetics

antibody-drug conjugate

tisotumab vedotin

Flag link:

Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger

Genmab gains on promising early success for daratumumab PhIII in multiple myeloma, but questions linger

Endpoints

Multiple Myeloma

clinical trials

Flag link:

Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years

Johnson & Johnson's 3 Biggest Sources of Growth Over the Next 10 Years

Motley Fool

specialty medicines

Flag link:

Looking for Darzalex sales expansion, J&J, Genmab hit a wall in lymphoma

Looking for Darzalex sales expansion, J&J, Genmab hit a wall in lymphoma

Fierce Pharma

non-Hodgkin's lymphoma

Flag link:

Johnson & Johnson May Already Have Its Remicade Replacement Well in Hand

Johnson & Johnson May Already Have Its Remicade Replacement Well in Hand

Motley Fool

Multiple Myeloma

Flag link:

Gilead licenses bi-specific tech from Danish biotech Genmab

Gilead licenses bi-specific tech from Danish biotech Genmab

BioPharma Dive

Gilead Sciences

Flag link:

Novartis stops PhIII trial of Genmab's Arzerra after buying rights from GSK

Novartis stops PhIII trial of Genmab's Arzerra after buying rights from GSK

Fierce Biotech

pemphigus vulgaris

Flag link:

J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex

J&J nabs an early OK for 'breakthrough' multiple myeloma blockbuster contender Darzalex

Fierce Biotech

Multiple Myeloma

Flag link:

J&J positions blockbuster contender daratumumab for a multiple myeloma showdown

J&J positions blockbuster contender daratumumab for a multiple myeloma showdown

Fierce Biotech

Multiple Myeloma

Bristol-Myers Squibb

Flag link:

Novo Nordisk ties the R&D knot with Genmab, and they're not focused on cancer

Novo Nordisk ties the R&D knot with Genmab, and they're not focused on cancer

Fierce Biotech

Flag link:

Novartis files leukemia drug Arzerra in the EU

Novartis files leukemia drug Arzerra in the EU

BioPharma Dive

chronic lymphocytic leukemia

Flag link:

Genmab shares rise on cancer drug's FDA license application

Genmab shares rise on cancer drug's FDA license application

Yahoo/Reuters

Multiple Myeloma

Flag link:

Amgen hands off an IL-15 drug--strings attached--for upstart effort on celiac disease

Amgen hands off an IL-15 drug--strings attached--for upstart effort on celiac disease

Fierce Biotech

Flag link:

JNJ launches PhII lymphoma study for daratumumab

JNJ launches PhII lymphoma study for daratumumab

Fierce Biotech

non-Hodgkin's lymphoma

Flag link:

J&J hands over $25M milestone for daratumumab progress

J&J hands over $25M milestone for daratumumab progress

Fierce Biotech

Flag link:

Pages